Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010668 | 1.00 | ADRB2 (0.71) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| SCHEMBL2957367 | 1.00 | ADRB2 (0.71) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| Bromide SCHEMBL3419252 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| Bromide SCHEMBL5670599 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| Bromide SCHEMBL3419254 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| Trifluoroacetic Acid SCHEMBL4862945 | 0.89 | ADRB2 (0.59) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| Trifluoroacetic Acid SCHEMBL4862950 | 0.89 | ADRB2 (0.59) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| SCHEMBL13596185 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1AOC3ADRB3KDM4E | |
| SCHEMBL29033215 | 0.83 | ADRB2 (0.60) | ADRB2ADRB1AOC3KDM4EL3MBTL1 | |
| SCHEMBL31450080 | 0.83 | ADRB2 (0.60) | ADRB2ADRB1AOC3KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075271-A1 | Crystalline beta2 adrenergic receptor agonist | THERAVANCE, INC. | 2005-04-07 | — | — | US | claimed |
| US-7846973-B2 | Chemical process and new crystalline form | THERAVANCE, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846973-B2 | Chemical process and new crystalline form | THERAVANCE, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846973-B2 | Chemical process and new crystalline form | THERAVANCE, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7772434-B2 | Crystalline form of a β2 adrenergic receptor agonist | THERAVANCE, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772434-B2 | Crystalline form of a β2 adrenergic receptor agonist | THERAVANCE, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772434-B2 | Crystalline form of a β2 adrenergic receptor agonist | THERAVANCE, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100125150-A1 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125150-A1 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125150-A1 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-07-05 | — | — | US | disclosed |
| EP-1730104-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| EP-1641744-A2 | CRYSTALLINE FORM OF B2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005095328-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| EP-1532104-A1 | CRYSTALLINE BETA-2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050075271-A1 | Crystalline beta2 adrenergic receptor agonist | THERAVANCE, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2004106279-A2 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004011416-A1 | CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885AOC3 2331/4885 |
| US-20100125150-A1 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885AOC3 2385/4885 |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885AOC3 2422/4885 |
| US-20050075271-A1 | Crystalline beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885AOC3 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.